This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors (Score-India)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: March 7, 2012
Last updated: July 8, 2013
Last verified: July 2013

This non-interventional, prospective, multi-centric, cross-sectional study is aimed to obtain the distribution of measurements of CIMT in Indian subjects and will involve approx. 30 investigative sites from all over the country. Each investigative site will be expected to enrol 50 subjects and Carotid intima-media thickness (CIMT) values will be taken for each individual as described in the protocol.

All the procedures could be completed in a single day, however due to any reason any study variable is not taken subject may be asked to come back for a second visit within 7 days of the first visit.

Carotid Intima- Media Thickness

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors in Asymptomatic Nationwide Indian Population (SCORE India)

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • CIMT values in centimeters (unit) of male and female subjects without established cardiovascular disease. [ Time Frame: at visit 1 ]

Enrollment: 1200
Study Start Date: May 2012
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
subjects who are meeting the inclusion criteria

Detailed Description:
A Study to derive normative distribution of CIMT and to determine its cOrrelation with cardiovascular Risk factors in asymptomatic nationwidE Indian population. (SCORE India)

Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Asymptomatic subjects with or without risk factors but not suffering from any established cardiovascular event.

Inclusion Criteria:

  • Provision of subject informed consent
  • Female or male aged 30 years and over

Exclusion Criteria:

  • Subjects with established cardiovascular event
  • Intake of lipid lowering drug in the past 3 month
  • Subjects with known hypersensitivity to carotid bulb
  • Pregnant or lactating women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01551875

Research Site
Ahmedabad, Gujarat, India
Research Site
Vadodara, Gujarat, India
Research Site
Gurgaon, Haryana, India
Research Site
Keshwapur, Hubli, India
Research Site
Nampally, Hyderabad, India
Research Site
Punjab, Jalanhar, India
Research Site
Bangalore, Karnataka, India
Research Site
Mangalore, Karnataka, India
Research Site
Mumbai, Maharashtra, India
Research Site
Nerul, Navi Mumbai, India
Research Site
Delhi, New Delhi, India
Research Site
Dhanvantri Nagar, Pondicherry, India
Research Site
Jipur, Rajasthan, India
Research Site
Chennai, Tamil Nadu, India
Research Site
Poonkunnam, Thrisur, India
Research Site
Pattom, Trivandum, India
Research Site
Noida, UP, India
Research Site
Varanasi, UP, India
Research Site
Ghaziabad, Uttar Pradesh, India
Research Site
Kolkata, West Bengal, India
Research Site
Chandigarh, India
Research Site
Indore, India
Research Site
Lucknow, India
Research Site
Pune, India
Sponsors and Collaborators
Study Director: Paurus M Irani, MD AstraZeneca Pharma India Ltd.
Principal Investigator: R R Kasliwal, DM Medanta, The Medicity, Gurgaon
  More Information

Responsible Party: AstraZeneca Identifier: NCT01551875     History of Changes
Other Study ID Numbers: NIS-CIN-XXX-2011/2
Study First Received: March 7, 2012
Last Updated: July 8, 2013

Keywords provided by AstraZeneca:
cardiovascular disease
correlation with cardiovascular Risk factors processed this record on August 16, 2017